Handel Viracta Therapeutics, Inc. - VIRX CFD
Føj til favorit- Opsummering
- Historisk Data
- Begivenheder
- Resultatopgørelse
- Saldo
- Cash flow
- Ejerskab
Handelsbetingelser
| Spænd | 0.06 | ||||||||
|
Long position, gebyr natten over
Long position overnight fee
Gå til platform | -0.024068% | ||||||||
|
Short position, gebyr natten over
Short position overnight fee
Gå til platform | 0.001846% | ||||||||
| Gebyr natten over, tid | 21:00 (UTC) | ||||||||
| Min. handlet mængde | 1 | ||||||||
| Valuta | USD | ||||||||
| Margen | 20% | ||||||||
| Aktiebørs | United States of America | ||||||||
| Kommission på handel | 0% |
*Information provided by Capital.com
Nøglestatistikker
| Tidligere luk* | 1.62 |
| Åben* | 1.58 |
| 1-Års Ændring* | -48.37% |
| Dagens Spænd* | 1.44 - 1.62 |
| 52-Ugers Spænd | 1.21-5.75 |
| Gennemsnitlig Volumen (10 dage) | 53.01K |
| Gennemsnitlig Volumen (3 måneder) | 1.90M |
| Market Cap | 63.38M |
| P/E-forhold | -100.00K |
| Udestående aktier | 38.41M |
| Omsætning | N/A |
| EPS | -1.30 |
| Dividend (Udbytte %) | N/A |
| Beta | 1.22 |
| Næste indtjeningsopgørelse | May 8, 2023 |
Al data kommer fra Refinitiv, med undtagelse af data markeret med en asterisk, som er *data fra Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Luk | Change | Change (%) | Åben | High | Low |
|---|---|---|---|---|---|---|
| Mar 20, 2023 | 1.50 | -0.08 | -5.06% | 1.58 | 1.62 | 1.43 |
| Mar 17, 2023 | 1.62 | 0.05 | 3.18% | 1.57 | 1.65 | 1.53 |
| Mar 16, 2023 | 1.57 | -0.05 | -3.09% | 1.62 | 1.67 | 1.52 |
| Mar 15, 2023 | 1.63 | -0.12 | -6.86% | 1.75 | 1.75 | 1.61 |
| Mar 14, 2023 | 1.73 | -0.02 | -1.14% | 1.75 | 1.80 | 1.70 |
| Mar 13, 2023 | 1.68 | 0.03 | 1.82% | 1.65 | 1.71 | 1.65 |
| Mar 10, 2023 | 1.66 | -0.02 | -1.19% | 1.68 | 1.70 | 1.63 |
| Mar 9, 2023 | 1.68 | -0.01 | -0.59% | 1.69 | 1.71 | 1.65 |
| Mar 8, 2023 | 1.69 | -0.07 | -3.98% | 1.76 | 1.77 | 1.68 |
| Mar 7, 2023 | 1.71 | 0.01 | 0.59% | 1.70 | 1.78 | 1.68 |
| Mar 6, 2023 | 1.68 | -0.02 | -1.18% | 1.70 | 1.77 | 1.67 |
| Mar 3, 2023 | 1.71 | 0.03 | 1.79% | 1.68 | 1.73 | 1.66 |
| Mar 2, 2023 | 1.69 | 0.07 | 4.32% | 1.62 | 1.70 | 1.62 |
| Mar 1, 2023 | 1.67 | 0.00 | 0.00% | 1.67 | 1.71 | 1.62 |
| Feb 28, 2023 | 1.66 | -0.06 | -3.49% | 1.72 | 1.73 | 1.63 |
| Feb 27, 2023 | 1.65 | -0.07 | -4.07% | 1.72 | 1.74 | 1.63 |
| Feb 24, 2023 | 1.72 | -0.07 | -3.91% | 1.79 | 1.82 | 1.67 |
| Feb 23, 2023 | 1.79 | -0.10 | -5.29% | 1.89 | 1.90 | 1.75 |
| Feb 22, 2023 | 1.88 | 0.04 | 2.17% | 1.84 | 1.94 | 1.80 |
| Feb 21, 2023 | 1.82 | -0.07 | -3.70% | 1.89 | 1.94 | 1.76 |
Viracta Therapeutics, Inc. Events
| Tid (UTC) (UTC) | Land | Begivenhed |
|---|---|---|
| No events scheduled | ||
- Årlig
- Pr kvartal
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Total omsætning | 0 | 0.12 | 2.073 | 0.237 | 0.669 |
| Omsætning | 0.12 | 2.073 | 0.237 | 0.669 | |
| Totale Driftsudgifter | 114.019 | 22.423 | 25.361 | 25.947 | 35.088 |
| Salgs/Generelle/Admin. Udgifter, Total | 15.437 | 10.164 | 9.949 | 11.332 | 13.548 |
| Forskning & Udvikling | 23.861 | 12.259 | 15.412 | 14.615 | 21.54 |
| Driftsindtægter | -114.019 | -22.303 | -23.288 | -25.71 | -34.419 |
| Renteindkomst (Udgift), Netto Ikke-Drift | -0.453 | -0.302 | -0.514 | -1.154 | -1.396 |
| Andre, Netto | -0.29 | 0.995 | 0.472 | 0.249 | 0.357 |
| Netto Indkomst Før Skat | -114.762 | -21.61 | -23.33 | -26.615 | -35.458 |
| Netto Indkomst Efter Skat | -114.762 | -21.61 | -23.33 | -26.615 | -35.458 |
| Netto Indkomst Før Ekstra Ting | -114.762 | -21.61 | -23.33 | -26.615 | -35.458 |
| Netto Indkomst | -114.762 | -21.61 | -23.33 | -26.615 | -35.458 |
| Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -114.762 | -21.61 | -23.33 | -26.615 | -35.458 |
| Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -114.762 | -21.61 | -23.33 | -26.615 | -35.458 |
| Fortyndelsesændring | |||||
| Fortyndet Netto Indkomst | -114.762 | -21.61 | -23.33 | -26.615 | -35.458 |
| Fortyndet Vægtet Gennemsnit Aktier | 31.8701 | 4.02657 | 2.48936 | 1.01661 | 0.70045 |
| Fortyndet EPS Uden Ekstraordinære Ting | -3.60093 | -5.36685 | -9.37188 | -26.1801 | -50.622 |
| Fortyndet Normaliseret EPS | -0.83279 | -5.01916 | -9.37188 | -26.1801 | -50.622 |
| Totale Ekstraordinære Ting | 0 | ||||
| Usædvanlig Udgift (Indkomst) | 88.221 | ||||
| Other Operating Expenses, Total | -13.5 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Total omsætning | 0 | 0 | 0 | 0 | 0 |
| Totale Driftsudgifter | 10.432 | 11.318 | 14.799 | 9.06 | 78.842 |
| Salgs/Generelle/Admin. Udgifter, Total | 4.336 | 4.015 | 3.711 | 3.871 | 3.84 |
| Forskning & Udvikling | 6.096 | 7.303 | 7.088 | 5.446 | 4.024 |
| Usædvanlig Udgift (Indkomst) | 0 | 0 | 4 | -0.257 | 84.478 |
| Other Operating Expenses, Total | 0 | 0 | 0 | 0 | -13.5 |
| Driftsindtægter | -10.432 | -11.318 | -14.799 | -9.06 | -78.842 |
| Renteindkomst (Udgift), Netto Ikke-Drift | -0.114 | -0.129 | -0.115 | -0.11 | -0.099 |
| Andre, Netto | 0 | 0 | 0 | 0 | -0.29 |
| Netto Indkomst Før Skat | -10.546 | -11.447 | -14.914 | -9.17 | -79.231 |
| Netto Indkomst Efter Skat | -10.546 | -11.447 | -14.914 | -9.17 | -79.231 |
| Netto Indkomst Før Ekstra Ting | -10.546 | -11.447 | -14.914 | -9.17 | -79.231 |
| Netto Indkomst | -10.546 | -11.447 | -14.914 | -9.17 | -79.231 |
| Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -10.546 | -11.447 | -14.914 | -9.17 | -79.231 |
| Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -10.546 | -11.447 | -14.914 | -9.17 | -79.231 |
| Fortyndet Netto Indkomst | -10.546 | -11.447 | -14.914 | -9.17 | -79.231 |
| Fortyndet Vægtet Gennemsnit Aktier | 37.5359 | 37.4929 | 37.3534 | 37.2214 | 15.1667 |
| Fortyndet EPS Uden Ekstraordinære Ting | -0.28096 | -0.30531 | -0.39927 | -0.24636 | -5.224 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Fortyndet Normaliseret EPS | -0.28096 | -0.30531 | -0.29218 | -0.25327 | 0.34595 |
- Årlig
- Pr kvartal
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Totale Nuværende Aktiver | 105.273 | 22.144 | 36.322 | 15.2 | 32.933 |
| Likvider og Kortsigtede Investeringer | 103.554 | 20.41 | 29.125 | 13.696 | 31.75 |
| Likvider & Lignende | 103.554 | 20.41 | 12.761 | 13.696 | 26.977 |
| Kortsigtede Investeringer | 16.364 | 0 | 4.773 | ||
| Prepaid Expenses | 1.719 | 1.734 | 1.697 | 1.504 | 1.183 |
| Total Assets | 108.552 | 23.247 | 37.24 | 15.324 | 34.334 |
| Property/Plant/Equipment, Total - Net | 0.882 | 0.273 | 0.82 | 0.011 | 0.02 |
| Total Current Liabilities | 9.084 | 3.31 | 9.416 | 11.323 | 12.678 |
| Accounts Payable | 2.901 | 0.479 | 0.791 | 1.393 | 1.697 |
| Accrued Expenses | 6.183 | 2.831 | 3.16 | 2.534 | 3.777 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 0 | 0 | 5.465 | 7.396 | 7.204 |
| Other Current Liabilities, Total | 0 | ||||
| Total Liabilities | 14.181 | 3.31 | 9.697 | 11.331 | 12.79 |
| Total Long Term Debt | 4.819 | 0 | 0 | 0 | 0 |
| Long Term Debt | 4.819 | 0 | |||
| Other Liabilities, Total | 0.278 | 0 | 0.281 | 0.008 | 0.112 |
| Total Equity | 94.371 | 19.937 | 27.543 | 3.993 | 21.544 |
| Preferred Stock - Non Redeemable, Net | 5.452 | 5.545 | 11.769 | 20.998 | 20.966 |
| Common Stock | 0.004 | 0.002 | 0.011 | 0.004 | 0.003 |
| Additional Paid-In Capital | 254.592 | 718.8 | 698.562 | 642.46 | 633.436 |
| Retained Earnings (Accumulated Deficit) | -165.677 | -704.41 | -682.8 | -659.469 | -632.854 |
| Other Equity, Total | 0 | 0.001 | 0 | -0.007 | |
| Total Liabilities & Shareholders’ Equity | 108.552 | 23.247 | 37.24 | 15.324 | 34.334 |
| Total Common Shares Outstanding | 37.4249 | 5.17364 | 3.18266 | 1.07069 | 0.97973 |
| Other Long Term Assets, Total | 2.397 | 0.83 | 0.098 | 0.113 | 1.381 |
| Other Current Assets, Total | 5.5 | ||||
| Total Preferred Shares Outstanding | 0.01025 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Totale Nuværende Aktiver | 95.373 | 105.273 | 113.015 | 125.142 | 132.304 |
| Likvider og Kortsigtede Investeringer | 92.199 | 103.554 | 110.983 | 122.721 | 129.181 |
| Likvider & Lignende | 92.199 | 103.554 | 110.983 | 122.721 | 129.181 |
| Prepaid Expenses | 3.174 | 1.719 | 2.032 | 2.421 | 3.123 |
| Total Assets | 98.387 | 108.552 | 116.54 | 128.679 | 136.209 |
| Property/Plant/Equipment, Total - Net | 0.759 | 0.882 | 0.987 | 0.857 | 1.078 |
| Other Long Term Assets, Total | 2.255 | 2.397 | 2.538 | 2.68 | 2.827 |
| Total Current Liabilities | 7.766 | 9.084 | 7.161 | 6.953 | 6.265 |
| Accounts Payable | 3.222 | 2.901 | 2.098 | 2.566 | 1.571 |
| Accrued Expenses | 4.544 | 6.183 | 5.063 | 3.554 | 4.121 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 0 | 0 | 0.833 | 0.573 | |
| Total Liabilities | 12.782 | 14.181 | 12.565 | 11.582 | 11.465 |
| Total Long Term Debt | 4.841 | 4.819 | 5.026 | 4.155 | 4.633 |
| Long Term Debt | 4.841 | 4.819 | 5.026 | 4.155 | 4.633 |
| Other Liabilities, Total | 0.175 | 0.278 | 0.378 | 0.474 | 0.567 |
| Total Equity | 85.605 | 94.371 | 103.975 | 117.097 | 124.744 |
| Preferred Stock - Non Redeemable, Net | 5.452 | 5.452 | 5.452 | 5.452 | 5.452 |
| Common Stock | 0.004 | 0.004 | 0.004 | 0.004 | 0.004 |
| Additional Paid-In Capital | 256.372 | 254.592 | 252.749 | 250.957 | 249.434 |
| Retained Earnings (Accumulated Deficit) | -176.223 | -165.677 | -154.23 | -139.316 | -130.146 |
| Total Liabilities & Shareholders’ Equity | 98.387 | 108.552 | 116.54 | 128.679 | 136.209 |
| Total Common Shares Outstanding | 37.4862 | 37.4249 | 37.2812 | 37.1408 | 37.0363 |
| Total Preferred Shares Outstanding | 0.01025 | 0.01025 | 0.01025 | 0.01025 | 0.01025 |
- Årlig
- Pr kvartal
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Netto indkomst/Startlinje | -114.762 | -21.61 | -23.33 | -26.615 | -35.458 |
| Likvider Fra Driftsaktiviteter | -18.851 | -21.439 | -22.185 | -24.404 | -36.142 |
| Likvider Fra Driftsaktiviteter | 0.178 | 0.009 | 0.009 | ||
| Ikke-Likvide Ting | 94.053 | 0.488 | 1.795 | 2.829 | 3.302 |
| Likvid Rente Betalt | 0.343 | 0.339 | 0.695 | 0.79 | 1.066 |
| Ændringer i Driftskapital | 1.68 | -0.317 | -0.65 | -0.627 | -3.995 |
| Likvider fra Investeringsaktiviteter | 12.891 | 16.407 | -16.285 | 4.78 | 29.748 |
| Kapitaludgifter | -0.252 | 0 | -0.026 | ||
| Andre Investerings-Cash-Flow-Ting, Total | 13.143 | 16.407 | -16.285 | 4.78 | 29.774 |
| Likvider fra Financieringsaktiviteter | 62.425 | 7.181 | 43.035 | 6.343 | 25.315 |
| Financiering af Cash-Flow-Ting | 0 | ||||
| Udstedelse (Pensionering) af Aktier, Netto | 62.659 | 12.681 | 45.082 | 6.343 | 32.93 |
| Udstedelse (Pensionering) af Gæld, Netto | -0.234 | -5.5 | -2.047 | 0 | -7.615 |
| Netto Ændring i Likviditet | 56.465 | 2.149 | 4.565 | -13.281 | 18.921 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -10.546 | -114.762 | -103.315 | -88.401 | -79.231 |
| Cash From Operating Activities | -11.363 | -18.851 | -11.64 | -4.042 | 2.551 |
| Cash From Operating Activities | 0.054 | 0.178 | 0.119 | 0.067 | 0.016 |
| Non-Cash Items | 1.772 | 94.053 | 92.245 | 86.541 | 85.412 |
| Cash Interest Paid | 0.102 | 0.343 | 0.257 | 0.142 | 0.084 |
| Changes in Working Capital | -2.643 | 1.68 | -0.689 | -2.249 | -3.646 |
| Cash From Investing Activities | 0 | 12.891 | 12.91 | 17.138 | 17.143 |
| Other Investing Cash Flow Items, Total | 0 | 13.143 | 13.143 | 17.143 | 17.143 |
| Cash From Financing Activities | 0.008 | 62.425 | 62.624 | 62.536 | 62.398 |
| Issuance (Retirement) of Stock, Net | 0.008 | 62.659 | 62.624 | 62.536 | 62.398 |
| Net Change in Cash | -11.355 | 56.465 | 63.894 | 75.632 | 82.092 |
| Capital Expenditures | -0.252 | -0.233 | -0.005 | ||
| Issuance (Retirement) of Debt, Net | -0.234 | 0 | 0 |
| Investornavn | Investortype | Procent udestående | Aktiebeholdning | Aktieændring | Beholdningsdato | IOmsætningsscore |
|---|---|---|---|---|---|---|
| aMoon Fund | Venture Capital | 19.2451 | 7392237 | 0 | 2022-06-08 | LOW |
| BVF Partners L.P. | Hedge Fund | 9.4105 | 3614662 | 0 | 2022-12-31 | LOW |
| Forward Ventures Services, LLC | Venture Capital | 6.9376 | 2664790 | 0 | 2022-04-19 | |
| Citadel Advisors LLC | Hedge Fund | 4.0449 | 1553679 | -8336 | 2022-12-31 | HIGH |
| Huang (Michael) | Individual Investor | 3.9958 | 1534815 | 1534815 | 2022-04-19 | |
| Rubric Capital Management LP | Hedge Fund | 3.4651 | 1330983 | 336182 | 2022-12-31 | MED |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 2.9885 | 1147912 | 33544 | 2022-12-31 | LOW |
| Medical Strategy GmbH | Investment Advisor | 2.3484 | 902057 | 0 | 2022-09-30 | LOW |
| Laurion Capital Management LP | Hedge Fund | 1.8172 | 698000 | 0 | 2022-12-31 | HIGH |
| Samsara BioCapital, LLC | Venture Capital | 1.7956 | 689709 | 0 | 2022-12-31 | LOW |
| Royston (Ivor) | Individual Investor | 1.775 | 681807 | 25219 | 2023-02-25 | MED |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 1.1536 | 443126 | -198343 | 2022-12-31 | LOW |
| MAI Capital Management, LLC | Investment Advisor/Hedge Fund | 1.1114 | 426916 | -210725 | 2022-12-31 | LOW |
| Adage Capital Management, L.P. | Hedge Fund | 0.781 | 300000 | 0 | 2022-12-31 | LOW |
| Aisling Capital Management LP | Investment Advisor/Hedge Fund | 0.7513 | 288571 | 0 | 2022-12-31 | LOW |
| Lytton (Laurence W) | Individual Investor | 0.6662 | 255876 | -200844 | 2021-12-31 | MED |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.5843 | 224438 | 6502 | 2022-12-31 | LOW |
| Millennium Management LLC | Hedge Fund | 0.5178 | 198904 | 48530 | 2022-12-31 | HIGH |
| Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 0.4676 | 179621 | 33290 | 2022-12-31 | LOW |
| Gilder Gagnon Howe & Co. LLC | Hedge Fund | 0.4205 | 161507 | -100 | 2022-12-31 | LOW |
Hvorfor vælge Capital.com? Vores tal taler for sig selv.
Capital.com Group500K+
Handlende
92K+
Månedlkige, aktive klienter
$53M+
Månedlig investeringsvolumen
$30M+
Hævet hver måned
Handelslommeregner
Udregn dit hypotetiske P&L hvis du havde åbnet en CFD-handel på en given dato (vælg en dato) og lukket den på en anden dato (vælg en dato).
Handelskurtage
0
- 1:1
Gearing
1:1
- 20
- 100
- 500
- 1000
- 10000
Investering
Handelsstørrelse (Gearing x Investering):
Åben
Luk
Short Long
Viracta Therapeutics, Inc. Company profile
Om Viracta Therapeutics, Inc.
Viracta Therapeutics, Inc. tidligere Sunesis Pharmaceuticals, Inc. er en virksomhed, der beskæftiger sig med præcisionsonkologi. Virksomheden fokuserer på udvikling af nye lægemidler, der er rettet mod virus-associerede maligniteter. Selskabet gennemfører kliniske forsøg for sin kombinationsproduktkandidat som behandling af recidiverende/refraktære Epstein-Barr-virus-positive lymfomer. Selskabet gennemfører tre kliniske forsøg for sin vigtigste produktkandidat, Nana-val, i EBV+ lymfomer og solide tumorer, herunder et fase II-registreringsforsøg med Nana-val i EBV+ lymfomer. Selskabets førende produktkandidat er en helt oral kombination af nanatinostat. Virksomhedens udviklingspipeline omfatter også vecabrutinib, en ikke-kovalent ITK/BTK-hæmmer i den kliniske fase, og VRx-510, en PDK-1-hæmmer i den prækliniske fase. Virksomhedens nye tilgang til syntetisk dødelighed er rettet mod EBV-genomet for at gøre det muligt at dræbe tumorcellerne ved at fremkalde ekspressionen af visse virale kinase-gener, som igen aktiverer et antiviralt lægemiddel.
| Industry: | Biotechnology & Medical Research (NEC) |
2533 S Coast Hwy 101
Suite 210
CARDIFF BY THE SEA
CALIFORNIA 92007
US
Resultatopgørelse
- Annual
- Quarterly
Folk ser også
Leder du stadig efter en mægler, du kan stole på?
Deltag sammen med 500.000+ handlende over hele verden, der valgte at handle hos Capital.com